If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 4 of 4
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function after Kidney Transplantation
Objective
Ravulizumab vs Placebo in High Risk DGF after Kidney Transplantation
Protocol No
SURG-ALEXION-AWAKE
Categories
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND)
Objective
Felzartamab for the Treatment of Late Antibody-Mediated Rejection in Kidney Transplant Recipients
Protocol No
SURG-BIOGEN-TRANSCEND
Categories
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 12 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Objective
VX-147 in APOL1- Mediated Proteinuric Kidney Disease
Protocol No
NEPH-VERTEX-VX21-147-301
Categories
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN)
Objective
Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy
Protocol No
NEPH-ALEXION-ALXN1210-IGAN-320
Categories